Editorial: Pem and the cost of multicycle maintenance

Journal of Thoracic Oncology

Volumn 5, Issue 8, 2010, Pages 1111-1112

  Learn, Peter A ^a   Bach, Peter B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; ERLOTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADVANCED CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY CONTROL; REIMBURSEMENT; SENSITIVITY ANALYSIS; UNITED KINGDOM; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; LUNG TUMOR; NOTE;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS;

EID: 77955118508     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181e7c425     Document Type: Editorial

References (11)

1. Klein R WR, Muehlenbein C, Liepa AM, et al. Cost-Effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010;5:1263-1272.
2. IMS Health Forecasts Continued Double-Digit Annual Growth of Cancer Therapeutics: Global Sales Expected to Exceed $75 Billion by 2012. 2008. Available at:. a46c6d4df3db4b3d88f611019418c22a/?vgnextoid=6e0f5e878e205210 VgnVCM100000ed152ca2RCRD&vgnextchannel=41a67900b55a5110V gnVCM10000071812ca2RCRD&vgnextfmt=default#. Accessed April 21, 2010.
3. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst 2009; 101:1044-1048.
4. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009;360:626-633.
5. Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008;100:888-897.
6. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
7. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276: 1253-1258.
8. Braithwaite RS, Meltzer DO, King JT Jr, et al. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349-356.
9. Neumann PJ, Palmer JA, Nadler E, et al. Cancer Therapy Costs Influence Treatment: A National Survey Of Oncologists. Health Aff (Millwood) 2010;29:196-202.
10. Smith T. Trends in National Spending Priorities, 1973-2006. Chicago, IL: University of Chicago, 2007.
11. Lung cancer (non-small-cell)-pemetrexed (maintenance): final appraisal determination. 2010. Available at: index.jsp?action=download&o=48303. Accessed April 21, 2010.